Innovate Biopharmaceuticals (INNT) Trading Down 8.9%
Shares of Innovate Biopharmaceuticals Inc (NASDAQ:INNT) fell 8.9% during mid-day trading on Tuesday . The company traded as low as $1.37 and last traded at $1.43. 1,003,034 shares were traded during mid-day trading, an increase of 40% from the average session volume of 718,872 shares. The stock had previously closed at $1.57.
The company has a debt-to-equity ratio of 0.02, a current ratio of 1.14 and a quick ratio of 0.63.
Innovate Biopharmaceuticals (NASDAQ:INNT) last released its earnings results on Monday, March 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.11).
About Innovate Biopharmaceuticals (NASDAQ:INNT)
Innovate Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH).
Recommended Story: What Does Beta Mean In Stock Selection
Receive News & Ratings for Innovate Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovate Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.